<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1449">
  <stage>Registered</stage>
  <submitdate>24/01/2007</submitdate>
  <approvaldate>24/01/2007</approvaldate>
  <nctid>NCT00427050</nctid>
  <trial_identification>
    <studytitle>A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel</studytitle>
    <scientifictitle>An Open-label, Multi-centre, Dose-escalation, Cohort Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel When Applied to a 25 cm2 Contiguous Actinic Keratoses Treatment Area on the Face or Face and Scalp.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PEP005-007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Actinic Keratoses</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEP005

Treatment: drugs: PEP005


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Optimal tolerated regime of PEP005 Topical Gel in patients, when administered as either two day or three day application schedules to a 25 cm2 contiguous AK treatment area on the face or face and scalp</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy at 2 or 3day application PEP005 Topical Gel at the MTD of 0.025% in the Expanded Cohort, and at 2 lower concs of 0.0175% and 0.0125% at either a 2 or 3day application, when applied to 25cm2 AK treatment area on face or face/scalp.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male patients at least 18 years of age.

          2. Post-menopausal female patients i.e., no menses for at least 12 consecutive months, or
             without a uterus.

          3. Four to eight clinically typical, visible and discrete AK lesions within a contiguous
             25 cm2 treatment area on the face or face and scalp.

        5. Ability to follow study instructions and likely to complete all study requirements.

        6. Written informed consent has been obtained. 7. Agreement from the patient to allow
        photographs of the selected AK treatment area to be taken and used as part of the study
        data package.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Skin and Cancer Foundation - Darlinghurst</hospital>
    <hospital>Southderm Pty Ltd - Kogarah</hospital>
    <hospital>St George Dermatology and Skin Cancer Centre - Level 3, 22 Belgrave St, Kogarah</hospital>
    <hospital>South East Dermatology - Belmont Specialist Centre, 1202 Creek Rd, Carina Heights</hospital>
    <hospital>The Skin Centre - Benowa</hospital>
    <hospital>Siller Medical - Brisbane</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode> - Kogarah</postcode>
    <postcode>2217 - Level 3, 22 Belgrave St, Kogarah</postcode>
    <postcode>4152 - Belmont Specialist Centre, 1202 Creek Rd, Carina Heights</postcode>
    <postcode>4217 - Benowa</postcode>
    <postcode> - Brisbane</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the optimal tolerated regime of PEP005 for the
      treatment of actinic keratoses of the face or face and scalp.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00427050</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janelle Katsamas</name>
      <address>Peplin Operations Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>